PTPN11 and Noonan syndrome: S502L and a similar S502P mutation of PTPN11/SHP2 were previously reported among human patients with Noonan syndrome or leukemia28–31 and predicted to be pathogenic through locking PTPN11 in an active conformation, thereby leading to sustained activation of RAS/MAPK cascade32.